Opioid-Sparing Effects of Flurbiprofen Axetil as an Adjuvant to Ropivacaine in Pre-Emptive Scalp Infiltration for Post-Craniotomy Pain: Study Protocol for a Multicenter, Randomized Controlled Trial
DOI: https://doi.org/10.2147/JPR.S399454
IF: 2.8319
2023-04-27
Journal of Pain Research
Abstract:Wei Zhang, 1, &ast Chunzhao Li, 2, &ast Chunmei Zhao, 3 Nan Ji, 2 Fang Luo 3 1 Department of Day Surgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, 100070, People's Republic of China; 2 Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, 100070, People's Republic of China; 3 Department of Day Surgery and Pain Management, Beijing Tiantan Hospital, Capital Medical University, Beijing, 100070, People's Republic of China &astThese authors contributed equally to this work Correspondence: Fang Luo, Department of Day Surgery and Pain Management, Beijing Tiantan Hospital, Capital Medical University, No. 119 West Road, South 4th Ring Road, Fengtai District, Beijing, 100070, People's Republic of China, Tel +86 10 59976664, Fax +86 10 67050177, Email Nan Ji, Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, No. 119 West Road, South 4th Ring Road, Fengtai District, Beijing, 100070, People's Republic of China, Email Background: Pain after craniotomy remains a poorly controlled problem that is mainly caused by the inflammatory reaction at the incision site. Nowadays, systemic opioids use, as first-line analgesics, is often limited because of adverse effects. Flurbiprofen axetil (FA) is a non-steroidal anti-inflammatory drug merged into emulsified lipid microspheres, which represent a strong affinity to inflammatory lesions. Local administration of flurbiprofen into a surgical wound has induced enhanced analgesic efficacy and few systemic or local adverse effects after oral surgery. However, the impact of local FA, as a non-opioid pharmacologic alternative, remains elusive on postoperative pain in craniotomy. In this study, we presume that pre-emptive infiltration of scalp with FA as an adjuvant to ropivacaine can lead to less sufentanil consumption postoperatively in patient controlled intravenous analgesia (PCIA) compared with ropivacaine alone. Methods/Design: We design a multicenter, randomized controlled study that will enroll 216 subjects who are planned to receive supratentorial craniotomy. Patients will receive pre-emptive infiltration of scalp either with 50 mg FA and 0.5% ropivacaine, or with 0.5% ropivacaine alone. Primary outcome is total consumption of sufentanil with PCIA device at 48 h postoperatively. Discussion: This is the first study attempting to explore the analgesic and safety profile of local FA as an adjuvant to ropivacaine for incisional pain in patients undergoing craniotomy. It will provide additional insights into the opioid-sparing analgesia pathways by local administration of NSAIDs for neurosurgery. Keywords: flurbiprofen axetil, pre-emptive analgesia, scalp infiltration, opioid-sparing, craniotomy, postoperative pain Post-craniotomy pain remains a major challenge for patients' outcome after neurosurgery. Recent studies reported that 55% to 80% of patients have experienced a moderate to severe pain within 48 h immediately after supratentorial craniotomy, 1 which may induce abrupt increases in blood pressure (BP) and heart rate (HR), even leading to an elevated intracranial pressure. Moreover, severe or prolonged acute pain following craniotomy is a significant predictor for the development of chronic pain states. 2,3 Nowadays, post-craniotomy pain is often insufficiently controlled due to the absence of international guidelines 4 and concerns for analgesic-related side effects. 5 The use of opioids, as the main-stray analgesics, can lead to profound neurological risks such as sedation, respiratory depression, nausea, vomiting, etc. 6 There has also been a well-recognized opioid tolerance induced by the widespread use of remifentanil in neurosurgery. 7 Furthermore, perioperative opioid prescriptions are associated with a substantial risk for chronic opioid-use disorders. 8 Consequently, opioids limitation imposed by the nature of neurosurgery has led to a suboptimal post-craniotomy pain management, which is associated with increased inpatient morbidity and mortality, prolonged hospital stay or higher 30-day readmission rate. Therefore, an optimal approach to pain control is paramount to minimize the requirement for opioids and to improve postprocedural comfort. Pain following craniotomy originates predominately from inflammatory sequelae after incisional damage in peri-cranial muscles and soft tissue. 9 Ropivacaine, as a long-acting reginal analgesic, has been popularly administrated for scalp infiltration. It has been demonstrated to reduce the demand for opioids and other rescue analgesics after craniotomy. 10,11 However, even -Abstract Truncated-
clinical neurology